NeuroFrontiers

Clinical practice guidelines from the American College of Chest Physicians provide recommendations for managing respiratory complications in patients with neuromuscular diseases, which can help inform our evaluation and treatment decisions. Joining Dr. Charles Turck to break down key insights from the CHEST guidelines and their impacts on clinical practice is Dr. Bimaje Akpa. Dr. Akpa is an Assistant Professor of Medicine in the Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine at the University of Minnesota.

A recent study on schizophrenia uncovered a significantly higher prevalence than previously estimated. The study also highlights ongoing struggles for patients, including low employment rates, poor general functioning, and limited access to adequate treatment. Join lead author Dr. Natalie Bareis as she discusses these findings and highlights the need for better policies and treatment accessibility. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.

Despite the availability of effective treatments for schizophrenia spectrum disorders, many patients are not receiving minimally adequate care based on a recent study. Tune in to hear Dr. Natalie Bareis discuss barriers to care, including the impact of substance use disorders and the limited availability of specialized programs, as well as how we can improve access and outcomes for patients with schizophrenia spectrum disorders. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.

Patients with neuromuscular conditions often exhibit respiratory symptoms that impact their airway clearance and gas exchange, making it increasingly difficult for them to breathe. However, effective assessment techniques and early intervention can help mitigate the progression of this dysfunction, potentially keeping patients from needing extended recovery time or even inpatient care. Joining Dr. Charles Turck to discuss the importance of informed, proactive intervention for respiratory symptoms in patients with neuromuscular conditions is Dr. Hank Mayer. Dr. Mayer is the Medical Director of the Pulmonary Function Laboratory at the Children's Hospital of Philadelphia and a Professor of Clinical Pediatrics at the University of Pennsylvania's Perelman School of Medicine.

Misinterpreted symptoms and limited access to treatment can make it difficult to manage myasthenia gravis among adolescents and young adults. Join Dr. Jonathan Strober as he explains how we can address gaps in care for this population. Dr. Strober is a Professor of Neurology at the University of California, San Francisco and the Director of the Neuromuscular Clinic at UCSF Benihoff Children’s Hospital.

Rozanolixizumab is a fast-acting myasthenia gravis treatment that reduces IgG levels by blocking the neonatal Fc receptor. Dr. Gil Wolfe explains how it compares to other treatment options like corticosteroids, taking side effects and quality of life into consideration. Dr. Wolf is a SUNY Distinguished Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences.

Generalized myasthenia gravis (gMG) is a complex autoimmune disease with a wide range of symptoms, from ocular issues to severe muscle weakness. As our understanding of the pathophysiology behind gMG evolves, so does our ability to improve patient management. Join Dr. Henry Kaminski as he examines emerging advancements in gMG treatment, including FcRN inhibitors and immune-targeting therapies. Dr. Kaminski is the Meta A. Neumann Professor of Neurology at the George Washington University School of Medicine and Health Sciences.

FcRn inhibitors provide a targeted approach to generalized myasthenia gravis (gMG) treatment by reducing pathogenic antibodies. These therapies offer fewer side effects compared to traditional treatments like corticosteroids, improving both disease control and quality of life. Dr. Nick Silvestri, a Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences, explains this treatment’s potential.

Amyloid-related imaging abnormalities (ARIA) can represent a significant clinical challenge in the acute management of some patients with Alzheimer's disease receiving anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). "Time Out: A Case-Based Deep Dive into the Challenges of ARIA Management" is an educational program designed to enhance clinicians' practical skills through the examination of complex, real-world case scenarios. This interactive program equips all members of the multidisciplinary care team with effective strategies for acute ARIA management, fostering confidence in handling intricate emergency situations. Join our expert panel to deepen your expertise and contribute meaningfully to patient care in the evolving landscape of ARIA.

Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdisciplinary approach. "The ARIA Toolkit: An Interdisciplinary Curriculum" is a comprehensive program designed to equip healthcare professionals with in-depth knowledge and practical skills for effective ARIA management. Featuring the latest advances in anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs), this educational format aims to prepare participants for real-world scenarios. Join our panel of expert faculty in this essential session to enhance team-based strategies and optimize patient outcomes.